223 related articles for article (PubMed ID: 25769384)
1. Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausible predictive and diagnostic markers.
Pal D; Sharma U; Khajuria R; Singh SK; Kakkar N; Prasad R
Gene; 2015 May; 562(2):145-51. PubMed ID: 25769384
[TBL] [Abstract][Full Text] [Related]
2. Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism.
Venturini L; Daidone MG; Motta R; Collini P; Spreafico F; Terenziani M; Piva L; Radice P; Perotti D; Zaffaroni N
Genes Chromosomes Cancer; 2011 Oct; 50(10):823-9. PubMed ID: 21769957
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues.
Fan Y; Liu Z; Fang X; Ge Z; Ge N; Jia Y; Sun P; Lou F; Björkholm M; Gruber A; Ekman P; Xu D
Clin Cancer Res; 2005 Jun; 11(12):4331-7. PubMed ID: 15958614
[TBL] [Abstract][Full Text] [Related]
4. hTERT expression in sporadic renal cell carcinomas.
Paradis V; Bièche I; Dargère D; Bonvoust F; Ferlicot S; Olivi M; Lagha NB; Blanchet P; Benoît G; Vidaud M; Bedossa P
J Pathol; 2001 Sep; 195(2):209-17. PubMed ID: 11592100
[TBL] [Abstract][Full Text] [Related]
5. Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology.
de Martino M; Taus C; Lucca I; Hofbauer SL; Haitel A; Shariat SF; Klatte T
Mol Carcinog; 2016 Oct; 55(10):1458-66. PubMed ID: 26294352
[TBL] [Abstract][Full Text] [Related]
6. Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles.
Plantinga MJ; Pascarelli KM; Merkel AS; Lazar AJ; von Mehren M; Lev D; Broccoli D
Mol Cancer Res; 2013 Jun; 11(6):557-67. PubMed ID: 23505069
[TBL] [Abstract][Full Text] [Related]
7. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.
Fasching CL; Bower K; Reddel RR
Cancer Res; 2005 Apr; 65(7):2722-9. PubMed ID: 15805271
[TBL] [Abstract][Full Text] [Related]
8. Increased alternative lengthening of telomere phenotypes of telomerase-negative immortal cells upon trichostatin--a treatment.
Jung AR; Yoo JE; Shim YH; Choi YN; Jeung HC; Chung HC; Rha SY; Oh BK
Anticancer Res; 2013 Mar; 33(3):821-9. PubMed ID: 23482750
[TBL] [Abstract][Full Text] [Related]
9. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
10. Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R.
Fujiwara M; Kamma H; Wu W; Yano Y; Homma S; Satoh H
Int J Oncol; 2006 Aug; 29(2):445-51. PubMed ID: 16820888
[TBL] [Abstract][Full Text] [Related]
11. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
Henson JD; Hannay JA; McCarthy SW; Royds JA; Yeager TR; Robinson RA; Wharton SB; Jellinek DA; Arbuckle SM; Yoo J; Robinson BG; Learoyd DL; Stalley PD; Bonar SF; Yu D; Pollock RE; Reddel RR
Clin Cancer Res; 2005 Jan; 11(1):217-25. PubMed ID: 15671549
[TBL] [Abstract][Full Text] [Related]
12. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
13. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma.
Gertler R; Rosenberg R; Stricker D; Friederichs J; Hoos A; Werner M; Ulm K; Holzmann B; Nekarda H; Siewert JR
J Clin Oncol; 2004 May; 22(10):1807-14. PubMed ID: 15143073
[TBL] [Abstract][Full Text] [Related]
14. Telomerase activity and telomere lengths: alterations in renal cell carcinomas.
Dahse R; Fiedler W; Junker K; Schlichter A; Schubert J; Claussen U
Kidney Int; 1999 Oct; 56(4):1289-90. PubMed ID: 10504477
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of positive telomerase activity in a chromophobe subtype of renal cell carcinoma.
Kinoshita H; Ogawa O; Mitsumori K; Kakehi Y; Terachi T; Yoshida O
J Urol; 1998 Jan; 159(1):245-51. PubMed ID: 9400489
[TBL] [Abstract][Full Text] [Related]
16. Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas.
Matsuo T; Shay JW; Wright WE; Hiyama E; Shimose S; Kubo T; Sugita T; Yasunaga Y; Ochi M
J Bone Joint Surg Am; 2009 Apr; 91(4):928-37. PubMed ID: 19339578
[TBL] [Abstract][Full Text] [Related]
17. Changes in telomere lengths in renal cell carcinomas.
Dahse R; Fiedler W; Ernst G; Kosmehl H; Schlichter A; Schubert J; Claussen U
Cell Mol Biol (Noisy-le-grand); 1996 Jun; 42(4):477-85. PubMed ID: 8828903
[TBL] [Abstract][Full Text] [Related]
18. Multiple mechanisms of telomere maintenance exist in liposarcomas.
Johnson JE; Varkonyi RJ; Schwalm J; Cragle R; Klein-Szanto A; Patchefsky A; Cukierman E; von Mehren M; Broccoli D
Clin Cancer Res; 2005 Aug; 11(15):5347-55. PubMed ID: 16061847
[TBL] [Abstract][Full Text] [Related]
19. [ALT--alternative lengthening of telomere].
Wu XM; Tang WR; Luo Y
Yi Chuan; 2009 Dec; 31(12):1185-91. PubMed ID: 20042385
[TBL] [Abstract][Full Text] [Related]
20. Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma.
Gertler R; Doll D; Maak M; Feith M; Rosenberg R
Cancer; 2008 May; 112(10):2173-80. PubMed ID: 18348304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
